| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | DAPK1; DAPK; Death-associated protein kinase 1; DAP kinase 1 |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human DAPK1. AA range:274-323 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets DAPK1 and detects endogenous levels of DAPK1 protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | DAPK1 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~160.3 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human DAPK1. AA range:274-323 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 1612; Mouse: 69635 |
| UniProt | P53355 (Human: P53355; Mouse: Q80YE7) |
Scientific Background
Death-associated protein kinase 1 is a positive mediator of gamma-interferon induced programmed cell death. DAPK1 encodes a structurally unique 160-kD calmodulin dependent serine-threonine kinase that carries 8 ankyrin repeats and 2 putative P-loop consensus sites. It is a tumor suppressor candidate. Alternative splicing results in multiple transcript variants.
Alternative Names
DAPK1; DAPK; Death-associated protein kinase 1; DAP kinase 1
Safety & Handling
| Target | DAPK1 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~160.3 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human DAPK1. AA range:274-323 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 1612; Mouse: 69635 |
| UniProt | P53355 (Human: P53355; Mouse: Q80YE7) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Death-associated protein kinase 1 is a positive mediator of gamma-interferon induced programmed cell death. DAPK1 encodes a structurally unique 160-kD calmodulin dependent serine-threonine kinase that carries 8 ankyrin repeats and 2 putative P-loop consensus sites. It is a tumor suppressor candidate. Alternative splicing results in multiple transcript variants.
Alternative Names
DAPK1; DAPK; Death-associated protein kinase 1; DAP kinase 1
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
